JP2019048895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019048895A5 JP2019048895A5 JP2018246722A JP2018246722A JP2019048895A5 JP 2019048895 A5 JP2019048895 A5 JP 2019048895A5 JP 2018246722 A JP2018246722 A JP 2018246722A JP 2018246722 A JP2018246722 A JP 2018246722A JP 2019048895 A5 JP2019048895 A5 JP 2019048895A5
- Authority
- JP
- Japan
- Prior art keywords
- citrullinated
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 108091006007 citrullinated proteins Proteins 0.000 claims 4
- 108010033040 Histones Proteins 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102000018803 Calgranulin A Human genes 0.000 claims 1
- 108010052500 Calgranulin A Proteins 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 108700010013 HMGB1 Proteins 0.000 claims 1
- 101150021904 HMGB1 gene Proteins 0.000 claims 1
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 108010065472 Vimentin Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000005048 vimentin Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894042P | 2013-10-22 | 2013-10-22 | |
| US61/894,042 | 2013-10-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Division JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177986A Division JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019048895A JP2019048895A (ja) | 2019-03-28 |
| JP2019048895A5 true JP2019048895A5 (enExample) | 2019-09-12 |
Family
ID=51866128
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Pending JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2018246722A Withdrawn JP2019048895A (ja) | 2013-10-22 | 2018-12-28 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2020177986A Pending JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Pending JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177986A Pending JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9688769B2 (enExample) |
| EP (1) | EP3060250A1 (enExample) |
| JP (3) | JP2016539925A (enExample) |
| CN (1) | CN105899231A (enExample) |
| AU (2) | AU2014338991B2 (enExample) |
| CA (1) | CA2928317A1 (enExample) |
| WO (1) | WO2015059168A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107868128A (zh) * | 2012-03-29 | 2018-04-03 | 诺夫免疫股份有限公司 | 抗tlr4抗体及其用途 |
| JP2016539925A (ja) | 2013-10-22 | 2016-12-22 | ノビミューン エスアー | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| EP3332256A1 (en) * | 2015-08-06 | 2018-06-13 | NovImmune SA | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| JP6872024B2 (ja) | 2016-10-04 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 合成分類指標の同定のためのシステムおよび方法 |
| CA3052720A1 (en) * | 2017-02-07 | 2018-08-16 | Orthogenics As | Biomarkers for diagnosing implant related risk of implant revision due to aseptic loosening |
| WO2020225549A1 (en) * | 2019-05-06 | 2020-11-12 | The Francis Crick Institute Limited | Method for preventing inflammation |
| IL294045A (en) * | 2019-12-20 | 2022-08-01 | Hudson Inst Med Res | Proteins that bind to cxcl10 and their uses |
| EP4138912A4 (en) * | 2020-04-20 | 2024-08-07 | Edesa Biotech Research Inc. | COMPOSITIONS AND METHODS FOR TREATING ACUTE RESPIRATORY DISTRESS SYNDROME |
| CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| PL1711531T3 (pl) * | 2003-12-10 | 2012-07-31 | Novimmune Sa | Przeciwciała neutralizujące przeciwko TLR4/MD-2 oraz sposoby ich zastosowania |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| AU2005272598B2 (en) | 2004-08-12 | 2011-11-17 | Helsinn Therapeutics (U.S.), Inc. | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| PL1830881T3 (pl) * | 2004-12-10 | 2010-11-30 | Novimmune Sa | Terapie skojarzone celowane na wiele receptorów Toll-podobnych i ich zastosowanie |
| BRPI0615277A2 (pt) | 2005-08-25 | 2009-08-04 | Creabilis Therapeutics Spa | conjugado de polìmeros de k-252a, composição farmacêutica compreendendo o referido conjugado, bem como uso do mesmo |
| CN101248105B (zh) * | 2005-08-25 | 2012-10-10 | 克雷毕里斯治疗股份公司 | K-252a及其衍生物的聚合物缀合物 |
| US20070148704A1 (en) | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
| US7712333B2 (en) | 2006-03-29 | 2010-05-11 | Asahi Glass Company, Limited | Method for smoothing a surface of a glass substrate for a reflective mask blank used in EUV lithography |
| ES2441189T3 (es) | 2007-05-14 | 2014-02-03 | Novimmune Sa | Polipéptidos de unión al receptor de Fc con funciones efectoras modificadas |
| CN101589491B (zh) | 2007-07-24 | 2011-07-27 | 松下电器产业株式会社 | 镍氢电池用负极材料及其处理方法以及镍氢电池 |
| WO2009138494A2 (en) | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| US9140701B2 (en) * | 2009-08-18 | 2015-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis |
| SI3757126T1 (sl) | 2010-11-05 | 2025-12-31 | Novartis Ag | Postopki za zdravljenje psoriatičnega artritisa z antagonisti il-17 |
| JP6289098B2 (ja) * | 2011-01-10 | 2018-03-07 | ノビミューン エスアー | 抗ｔｌｒ４抗体およびその使用法 |
| US20140378531A1 (en) * | 2012-02-01 | 2014-12-25 | New York University | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| US20160159922A1 (en) | 2013-07-24 | 2016-06-09 | Vilara Ab | Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis |
| JP2016539925A (ja) | 2013-10-22 | 2016-12-22 | ノビミューン エスアー | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
-
2014
- 2014-10-22 JP JP2016525584A patent/JP2016539925A/ja active Pending
- 2014-10-22 EP EP14793805.4A patent/EP3060250A1/en not_active Withdrawn
- 2014-10-22 US US14/520,904 patent/US9688769B2/en active Active
- 2014-10-22 AU AU2014338991A patent/AU2014338991B2/en not_active Ceased
- 2014-10-22 CN CN201480070143.8A patent/CN105899231A/zh active Pending
- 2014-10-22 WO PCT/EP2014/072606 patent/WO2015059168A1/en not_active Ceased
- 2014-10-22 CA CA2928317A patent/CA2928317A1/en not_active Abandoned
-
2017
- 2017-06-26 US US15/632,882 patent/US10556960B2/en active Active
-
2018
- 2018-12-28 JP JP2018246722A patent/JP2019048895A/ja not_active Withdrawn
-
2020
- 2020-09-11 AU AU2020230333A patent/AU2020230333A1/en not_active Abandoned
- 2020-10-23 JP JP2020177986A patent/JP2021006592A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019048895A5 (enExample) | ||
| CN112574307B (zh) | 抗人Claudin18.2抗体及其应用 | |
| ES2734130T3 (es) | Anticuerpos específicos de complejos y fragmentos de anticuerpo y su uso | |
| JP2020522261A5 (enExample) | ||
| Aletaha et al. | Therapeutic implications of autoantibodies in rheumatoid arthritis | |
| JP2016539925A5 (enExample) | ||
| ES2989669T3 (es) | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| US10590188B2 (en) | Antibody | |
| JP2012012402A5 (enExample) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| Von Büdingen et al. | Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce “oligoclonal bands” | |
| JP7331168B2 (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| JP2018507254A5 (enExample) | ||
| US20230236178A1 (en) | SPR-based dual-binding assay for the functional analysis of multispecific molecules | |
| CN112703204B (zh) | 针对可溶性bcma的抗体 | |
| CN117069848B (zh) | 抗人cd146兔单克隆抗体及其应用 | |
| RU2016106708A (ru) | Лекарственное средство, содержащее антитело к фосфолипазе d4 | |
| US9079942B2 (en) | CDR-anchored amplification method | |
| CN116554323A (zh) | 人源化抗il21抗体的开发和应用 | |
| CN117043187A (zh) | GARP/TGFβ1抗体及其应用 | |
| Sadeghian-Rizi et al. | Production of novel camelid anti-CXCL10 specific polyclonal antibodies and evaluation of their bioreactivity | |
| CN115335402B (zh) | 特异性抗原结合分子,其制备方法及医药用途 | |
| Van Gompel et al. | Anti-MDA5 monoclonal antibodies from patients with dermatomyositis-B cell characteristics and differential targeting of the helicase domains | |
| KR102896511B1 (ko) | SIRPα 변이체에 특이적으로 결합하는 항체 |